Researchers said that a new software tool may help doctors eliminate mistakes when judging whether a spot that turns up on a smoker's lung scan is cancerous or not.
The clinical risk assessment method described in the New England Journal of Medicine helped correctly decide nine times out of 10 whether a spot or lesion was benign or malignant.
Computed tomography (CT) scans can save lives, but they are imperfect and can also lead to unnecessary surgery as much as 25 percent of the time, research has shown.
"This is extremely good news for everyone -- from the people who are high risk for developing lung cancer to the radiologists, respirologists and thoracic surgeons who detect and treat it," said Lam, a professor of medicine at the University of British Columbia.
The prediction model includes a risk calculator that assesses age, sex, family history, emphysema, location of the nodule and other characteristics.
"Reducing the number of needless tests and increasing rapid, intensive diagnostic workups in individuals with high-risk nodules are major goals of the model," said Martin Tammemagi, an epidemiologist at Brock University who developed it.
Researchers tested the tool in a population of nearly 3,000 people, including current and former smokers aged 50 to 75 who had undergone low-dose CT screening.
Researchers found that bigger nodules did not always mean cancer, and that cancers were more often found in the upper parts of the lung than the lower lobes.
The risk analysis model helped correctly determine whether the nodule was cancerous or not 94 percent of the time, which the researchers described as "excellent predictive accuracy."
Furthermore, it helped diagnose tricky small nodules that are at most 10 millimeters in size 90 percent of the time.
"Previous prediction models for lung nodules were hospital-based or clinic-based and showed a high prevalence of lung cancer -- 23 to 75 percent, as compared with 5.5 percent in our study," said the article.
"Our models are coupled with risk calculators, which make possible the rapid and easy calculation of lung-cancer risk given the characteristics of the person and the nodules."
The approach could save money and cut down on false positives, said Christine Berg, co-principal investigator of the National Lung Screening Trial, describing it as "a major advance for clinicians performing lung cancer screening."
"Coupled with continued public health efforts to lower cigarette smoking, this work will have international impact on the leading cause of cancer death worldwide."